Compared to patients with tyrosine kinase inhibitor (TKI)-sensitizing EGFR mutations, NSCLC patients with EGFR exon 18 mutations generally respond slightly worse to first-generation (1G) EGFR-TKI (7, 10, 11). Here, EGFR is linked to non-small cell lung carcinoma.